Issue 28

CDMO Specialization Takes Center Stage in 2025

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

The Rising Specialization of CDMOs

As the demand for advanced therapies continues to grow, CDMOs are fast becoming the solution for biopharma companies that need specialized expertise and capabilities that are scalable for their drug development and commercialization. 

Read more here.

FEATURED STORIES

Terumo Launches Injection Filter Needle as Part of INFINO™ Development Program

Read more here.

Adare Pharma Solutions Expands in Pennsylvania, Welcomes Governor Shapiro

Read more here.

SCHOTT Pharma Unveils Next-Generation Polymer Syringe System

Read more here.

Tanvex BioPharma Completes Acquisition of Bora Biologics

Read more here.

Thermo Fisher Anticipates CDMO Growth Amid Industry Shifts

Read more here.

BioDuro Expands Peptide Synthesis with New Shanghai Facility

Read more here.

Novo Holdings Plans to Double Catalent's Size Amid U.S. Manufacturing Focus

Read more here.

DotBio and Bora Biologics Join Forces to Advance DB007

Read more here.

Lotte Biologics Unveils Dual CDMO Strategy in U.S. and Korea

Read more here.

Samsung Biologics Plans Sixth Manufacturing Plant

Read more here.

Aragen Secures $100 Million to Expand CDMO Services

Read more here.

BioCina and NovaCina Merge to Strengthen Australian CDMO Industry

Read more here.

Moderna Secures U.S. Government Grant for Avian Influenza Vaccine Development

Read more here.

Samsung Biologics Secures Record USD 1.4 Billion Contract with European Client

Read more here.